Affiliation: Mayo Clinic
- Renal function following combination chemotherapy with ifosfamide and cisplatin in patients with osteogenic sarcomaC Arndt
Department of Pediatrics and Adolescent Medicine, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
Med Pediatr Oncol 32:93-6. 1999....
- Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803Carola A S Arndt
Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 27:5182-8. 2009....
- Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology GroupCarola A S Arndt
Mayo Clinic and Foundation, Rochester, Minnesota, USA
Pediatr Blood Cancer 50:33-6. 2008..Treatment with alternating cycles of non-cross-resistant chemotherapy has been used in a number of diseases with good results...
- Significance of persistent mature rhabdomyoblasts in bladder/prostate rhabdomyosarcoma: Results from IRS IVCarola A S Arndt
Department of Pediatrics and Adolescent Medicine, Mayo Medical School, Mayo Clinic and Foundation, Rochester, MN 55905, USA
J Pediatr Hematol Oncol 28:563-7. 2006..Sequential biopsies are subject to sampling error and should only be performed in the context of protocol-directed therapy to avoid unnecessary radical surgeries...
- Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology GroupCarola A S Arndt
Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Clin Cancer Res 16:4024-30. 2010....
- Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamideC Arndt
Department of Pediatric Hematology Oncology, Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 22:1894-901. 2004..To evaluate the spectrum of and determine the risk factors for the development of liver toxicity (hepatopathy) after therapy with vincristine, dactinomycin, and cyclophosphamide (VAC) for rhabdomyosarcoma in children and adolescents...
- Does bladder preservation (as a surgical principle) lead to retaining bladder function in bladder/prostate rhabdomyosarcoma? Results from intergroup rhabdomyosarcoma study ivCarola Arndt
Mayo Clinic, Rochester, Minnesota, Duke University Medical Center, Durham, North Carolina, USA
J Urol 171:2396-403. 2004....
- Fas expression in lung metastasis from osteosarcoma patientsNancy Gordon
Division of Pediatrics, Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, and Division of Pediatrics Hematology Oncology, Mayo Clinic, Rochester, MN, USA
J Pediatr Hematol Oncol 27:611-5. 2005..0013). These data indicate that loss of Fas may be one mechanism by which OS cells evade host resistance in the lung. Chemotherapy may induce regression by upregulating Fas...
- Rothmund-Thomson syndrome due to RECQ4 helicase mutations: report and clinical and molecular comparisons with Bloom syndrome and Werner syndromeN M Lindor
Department of Medical Genetics, Mayo Clinic, Rochester, Minnesota 55905, USA
Am J Med Genet 90:223-8. 2000..These three disorders all manifest abnormal growth, premature aging, and predisposition to site-specific malignancies. The clinical and molecular aspects of RTS, Bloom syndrome, and Werner syndrome are compared and contrasted...
- Veno-occlusive disease of the liver after blood and marrow transplantation: analysis of pre- and post-transplant risk factors associated with severity and results of therapy with tissue plasminogen activatorMark R Litzow
Division of Hematology and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
Leuk Lymphoma 43:2099-107. 2002..01) and maximum blood urea level (P = 0.03). Ten patients (all with creatinine levels > or = 150 micromol/l) were treated with tissue plasminogen activator; only two had a significant response and only one survived beyond day 120...
- Marrow irradiation with high-dose 153Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemiaVilmarie Rodriguez
Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN 55905, USA
Leuk Lymphoma 47:1583-92. 2006..Thus, in adolescents and adults, 153Sm-EDTMP may provide a relatively simple and effective means for using irradiation to eliminate AML within the marrow...
- Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gutVilmarie Rodriguez
Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Pediatr Blood Cancer 49:212-5. 2007..In case 2, corticosteroid-unresponsive grade 3 acute liver and gut GVHD developed on day +37. In both patients, GVHD responded to the infliximab-daclizumab regimen without toxicity and immunosuppressive therapy was discontinued...
- Low toxicity and efficacy of (153)samarium-EDTMP and melphalan as a conditioning regimen for secondary acute myelogenous leukemiaVilmarie Rodriguez
Division of Pediatric Hematology Oncology, Mayo Clinic, Rochester, MN 55905, USA
Pediatr Transplant 9:122-6. 2005..She achieved engraftment on day +23. Three years after transplantation, she continues to have complete remission. Samarium and melphalan constitute a well-tolerated regimen with potential antileukemic activity...
- High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastasesPeter M Anderson
Department of Pediatrics, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
J Clin Oncol 20:189-96. 2002..Because the dose-limiting toxicity of (153)Sm-EDTMP is thrombocytopenia, a dose-escalation trial using peripheral-blood progenitor cells (PBPCs) or marrow support was conducted to treat metastatic bone cancer...
- Aerosolized granulocyte macrophage colony-stimulating factor (GM-CSF) therapy in metastatic cancerRavi D Rao
Department of Medical Oncology, Mayo Clinic, 200, 2nd Street SW, Rochester, Minnesota 55905, USA
Am J Clin Oncol 26:493-8. 2003..In one patient, we have evidence of upregulation of melanoma-specific cytotoxic T-cells. Further study is warranted to understand the impact of this therapy on the natural history of metastatic cancer...
- Diagnosis and management of bone malignancy in adolescenceJonathan S C Caudill
Division of Pediatric Hematology Oncology, Department of Pediatrics, Mayo Clinic, 200 First Street SW, Rochester, MN 55901, USA
Adolesc Med State Art Rev 18:62-78, ix. 2007..Survivorship issues in children and adolescents treated for these malignancies are discussed...
- Cerebral venous sinus thrombosis associated with essential thrombocytosis in a pediatric patientAshley W Jensen
Department of Radiation Oncology, Mayo Clinic, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
J Pediatr Hematol Oncol 29:156-9. 2007..Platelet counts were well controlled after 16 months of follow-up, and no further thrombotic events occurred. Mucositis was the main adverse effect of treatment...
- Intraabdominal desmoplastic small round cell tumors: a diagnostic and therapeutic challengeImran Hassan
Department of Surgery, Mayo Clinic, Rochester, MN 55905, USA
Cancer 104:1264-70. 2005..To the authors' knowledge, only limited data are available on the natural history and optimal treatment of this disease...
- Delayed radiotherapy following dose intensive chemotherapy for parameningeal rhabdomyosarcoma (PM-RMS) of childhoodJames G Douglas
Department of Radiation Oncology, University of Washington Affiliated Hospitals, Seattle, WA, United States
Eur J Cancer 43:1045-50. 2007..To evaluate the local control rates and survival rates of patients with Group III parameningeal rhabdomyosarcoma (PM-RMS) treated with a dose intensive chemotherapy regimen followed by irradiation...
- Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapyDouglas S Hawkins
Department of Pediatrics, Children s Hospital and Regional Medical Center, Seattle, Washington 98105, USA
Cancer 98:2447-56. 2003..The goal of the current study was to define the clinical features and outcome of recurrent osteosarcoma (OS) in children and young adults initially treated with contemporary chemotherapy...
- Alveolar soft-part sarcoma responsive to intensive chemotherapyH James Nickerson
Department of Pediatrics, Marshfield Clinic, WI 54449, USA
J Pediatr Hematol Oncol 26:233-5. 2004..Following intensive multiagent chemotherapy, pulmonary metastases showed in vivo evidence of tumor death. The patient has remained disease-free for 10 years following treatment...
- The impact of surgical excision in chest wall rhabdomyosarcoma: a report from the Children's Oncology GroupAndrea Hayes-Jordan
University of Texas MD Anderson Cancer Center, Box 87, Houston, TX 77030, USA
J Pediatr Surg 43:831-6. 2008..Chest wall RMS is a site in which the limitations of surgical excision are realized. We aim to determine the impact of surgical excision in chest wall RMS...
- Intrathecal mafosfamide: a preclinical pharmacology and phase I trialSusan M Blaney
Texas Children s Cancer Center, 6621 Fannin St, CC 1410 00, Houston, TX 77030 2399, USA
J Clin Oncol 23:1555-63. 2005..A phase I and pharmacokinetic study of IT mafosfamide was performed to determine a dose for subsequent phase II trials...